Comparative Pharmacology
Head-to-head clinical analysis: DECADRON versus DEXONE 1 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON versus DEXONE 1 5.
DECADRON vs DEXONE 1.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor and modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It also suppresses adrenal function by inhibiting ACTH secretion.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
0.75-9 mg/day orally in divided doses every 6-12 hours; or 0.5-9 mg/day IM/IV in divided doses every 12 hours for acute conditions; for cerebral edema, IV loading dose of 10 mg followed by 4 mg IM/IV every 6 hours.
1.5 mg orally once daily
None Documented
None Documented
Terminal half-life: 3-4 hours (plasma); biological half-life: 36-54 hours (due to intracellular receptor binding); clinical context: duration of HPA axis suppression longer than plasma half-life
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Renal (65-80% as 17-hydroxycorticosteroids and 20-hydroxycorticosteroids after hepatic metabolism); biliary/fecal (minor, <10%)
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Category C
Category C
Corticosteroid
Corticosteroid